---
document_datetime: 2025-12-17 23:29:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dacogen.html
document_name: dacogen.html
version: success
processing_time: 0.1176241
conversion_datetime: 2025-12-25 06:46:32.969529
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dacogen

[RSS](/en/individual-human-medicine.xml/66711)

##### Authorised

This medicine is authorised for use in the European Union

decitabine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Related content](#related-content-70339)
- [More information on Dacogen](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Dacogen. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Dacogen.

Expand section

Collapse section

## What is Dacogen?

Dacogen is a powder that is made up into a solution for infusion (drip) into a vein. It contains the active substance decitabine.

## What is Dacogen used for?

Dacogen is used to treat adults with newly diagnosed acute myeloid leukaemia (AML), a type of cancer affecting the white blood cells. It is used in patients who are not eligible for standard induction chemotherapy (initial treatment with cancer medicines).

Because the number of patients with AML is low, the disease is considered 'rare', and Dacogen was designated an 'orphan medicine' (a medicine used in rare diseases) on 8 June 2006.

## How is Dacogen used?

Dacogen can only be obtained with a prescription. Treatment with Dacogen should be started under the supervision of a doctor who has experience in the use of chemotherapy.

Dacogen is given as an infusion into a vein over one hour. The dose is calculated using the patient's height and weight. In a 4-week treatment cycle, Dacogen is given daily for the first 5 days. At least 4 treatment cycles are recommended but they can be continued for as long as the AML remains under control. If a patient develops certain severe side effects, the doctor may decide to delay or stop Dacogen treatment.

## How does Dacogen work?

The active substance in Dacogen, decitabine, is a cytidine deoxynucleoside analogue. This means that it is similar to cytidine deoxynucleoside, a fundamental component of the DNA (genetic material) of cells. In the body, decitabine is converted into decitabine triphosphate, which is then incorporated into the DNA where it blocks the activity of enzymes called DNA methyltransferases (DNMTs). These enzymes promote the development and progression of cancer. By blocking DNMTs, decitabine will prevent the increase of tumour cells and lead to their death.

## How has Dacogen been studied?

Dacogen has been studied in one main study involving 485 adults, who were newly diagnosed with AML but were not eligible for standard induction chemotherapy. Dacogen was compared with either supportive care (any medicine or technique to help patients, excluding cancer medicines or surgery) or low-dose cytarabine (another cancer medicine). Treatment was given for as long as patients benefited from it. The main measure of effectiveness was how long the patients lived.

## What benefit has Dacogen shown during the studies?

Patients receiving Dacogen lived for an average of 7.7 months compared with 5.0 months for patients receiving supportive care or treatment with cytarabine.

## What is the risk associated with Dacogen?

The most common side effects with Dacogen (seen in more than 35% of patients) are fever, anaemia (low red blood cell count) and thrombocytopenia (low blood platelet count). The most common serious side effects (seen in more than 20% of patients) include pneumonia (lung infection), thrombocytopenia, neutropenia (low blood count of neutrophils, a type of white blood cell), febrile neutropenia (low white blood cell count with fever) and anaemia.

Dacogen must not be used in people who are breastfeeding. As it is not known whether the active substance is excreted in breast milk, in the event that a patient is breastfeeding, they must discontinue breastfeeding if they require treatment with Dacogen.

For the full list of all restrictions and side effects reported with Dacogen, see the package leaflet.

## Why has Dacogen been approved?

The CHMP noted that the improvement in survival with Dacogen in patients with AML was modest but relevant, as the benefits of current treatments are limited in patients who are not eligible for standard induction chemotherapy. There were no major safety concerns with Dacogen and the overall safety profile was similar to that of low-dose cytarabine but some side effects such as infections and neutropenia were more common with Dacogen. The CHMP decided that Dacogen's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Dacogen?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dacogen have been included in the summary of product characteristics and the package leaflet.

## Other information about Dacogen

The European Commission granted a marketing authorisation valid throughout the European Union for Dacogen on 20 September 2012.

For more information about treatment with Dacogen, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Dacogen : EPAR - Summary for the public

Adopted

Reference Number: EMA/499966/2012

English (EN) (77.21 KB - PDF)

**First published:** 16/10/2012

**Last updated:** 29/07/2016

[View](/en/documents/overview/dacogen-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-665)

български (BG) (103 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/bg/documents/overview/dacogen-epar-summary-public_bg.pdf)

español (ES) (75.93 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/es/documents/overview/dacogen-epar-summary-public_es.pdf)

čeština (CS) (102.41 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/cs/documents/overview/dacogen-epar-summary-public_cs.pdf)

dansk (DA) (75.19 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/da/documents/overview/dacogen-epar-summary-public_da.pdf)

Deutsch (DE) (77.07 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/de/documents/overview/dacogen-epar-summary-public_de.pdf)

eesti keel (ET) (74.9 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/et/documents/overview/dacogen-epar-summary-public_et.pdf)

ελληνικά (EL) (104.4 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/el/documents/overview/dacogen-epar-summary-public_el.pdf)

français (FR) (76.87 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/fr/documents/overview/dacogen-epar-summary-public_fr.pdf)

hrvatski (HR) (96.34 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/hr/documents/overview/dacogen-epar-summary-public_hr.pdf)

italiano (IT) (75.52 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/it/documents/overview/dacogen-epar-summary-public_it.pdf)

latviešu valoda (LV) (100.28 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/lv/documents/overview/dacogen-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (100.48 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/lt/documents/overview/dacogen-epar-summary-public_lt.pdf)

magyar (HU) (96.37 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/hu/documents/overview/dacogen-epar-summary-public_hu.pdf)

Malti (MT) (103.32 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/mt/documents/overview/dacogen-epar-summary-public_mt.pdf)

Nederlands (NL) (75.74 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/nl/documents/overview/dacogen-epar-summary-public_nl.pdf)

polski (PL) (103.09 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/pl/documents/overview/dacogen-epar-summary-public_pl.pdf)

português (PT) (76.24 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/pt/documents/overview/dacogen-epar-summary-public_pt.pdf)

română (RO) (97.73 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/ro/documents/overview/dacogen-epar-summary-public_ro.pdf)

slovenčina (SK) (100.75 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/sk/documents/overview/dacogen-epar-summary-public_sk.pdf)

slovenščina (SL) (96.29 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/sl/documents/overview/dacogen-epar-summary-public_sl.pdf)

Suomi (FI) (76.88 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/fi/documents/overview/dacogen-epar-summary-public_fi.pdf)

svenska (SV) (75.49 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

29/07/2016

[View](/sv/documents/overview/dacogen-epar-summary-public_sv.pdf)

Dacogen : EPAR - Risk-management-plan summary

English (EN) (286.52 KB - PDF)

**First published:** 20/02/2019

**Last updated:** 03/06/2024

[View](/en/documents/rmp-summary/dacogen-epar-risk-management-plan-summary_en.pdf)

## Product information

Dacogen : EPAR - Product Information

English (EN) (251.14 KB - PDF)

**First published:** 16/10/2012

**Last updated:** 02/10/2024

[View](/en/documents/product-information/dacogen-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-218)

български (BG) (360.09 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/bg/documents/product-information/dacogen-epar-product-information_bg.pdf)

español (ES) (248.16 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/es/documents/product-information/dacogen-epar-product-information_es.pdf)

čeština (CS) (266.45 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/cs/documents/product-information/dacogen-epar-product-information_cs.pdf)

dansk (DA) (251.56 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/da/documents/product-information/dacogen-epar-product-information_da.pdf)

Deutsch (DE) (268.63 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/de/documents/product-information/dacogen-epar-product-information_de.pdf)

eesti keel (ET) (248.16 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/et/documents/product-information/dacogen-epar-product-information_et.pdf)

ελληνικά (EL) (301.2 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/el/documents/product-information/dacogen-epar-product-information_el.pdf)

français (FR) (245.46 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/fr/documents/product-information/dacogen-epar-product-information_fr.pdf)

hrvatski (HR) (233.68 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/hr/documents/product-information/dacogen-epar-product-information_hr.pdf)

íslenska (IS) (263.04 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/is/documents/product-information/dacogen-epar-product-information_is.pdf)

italiano (IT) (228.76 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/it/documents/product-information/dacogen-epar-product-information_it.pdf)

latviešu valoda (LV) (470.75 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/lv/documents/product-information/dacogen-epar-product-information_lv.pdf)

lietuvių kalba (LT) (266.68 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/lt/documents/product-information/dacogen-epar-product-information_lt.pdf)

magyar (HU) (258.32 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/hu/documents/product-information/dacogen-epar-product-information_hu.pdf)

Malti (MT) (279.2 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/mt/documents/product-information/dacogen-epar-product-information_mt.pdf)

Nederlands (NL) (247.48 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/nl/documents/product-information/dacogen-epar-product-information_nl.pdf)

norsk (NO) (238.51 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/no/documents/product-information/dacogen-epar-product-information_no.pdf)

polski (PL) (274.48 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/pl/documents/product-information/dacogen-epar-product-information_pl.pdf)

português (PT) (304.47 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/pt/documents/product-information/dacogen-epar-product-information_pt.pdf)

română (RO) (283.42 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/ro/documents/product-information/dacogen-epar-product-information_ro.pdf)

slovenčina (SK) (261.75 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/sk/documents/product-information/dacogen-epar-product-information_sk.pdf)

slovenščina (SL) (251.61 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/sl/documents/product-information/dacogen-epar-product-information_sl.pdf)

Suomi (FI) (248.34 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

09/12/2025

[View](/fi/documents/product-information/dacogen-epar-product-information_fi.pdf)

svenska (SV) (235.89 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

02/10/2024

[View](/sv/documents/product-information/dacogen-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0050 01/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dacogen : EPAR - All Authorised presentations

English (EN) (24.96 KB - PDF)

**First published:** 16/10/2012

**Last updated:** 21/07/2017

[View](/en/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-713)

български (BG) (27.77 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/bg/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_bg.pdf)

español (ES) (24.71 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/es/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_es.pdf)

čeština (CS) (26.59 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/cs/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (26.27 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/da/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.48 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/de/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (24.82 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/et/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (27.59 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/el/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_el.pdf)

français (FR) (25.13 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/fr/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25.35 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/hr/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (25.83 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/is/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_is.pdf)

italiano (IT) (24.79 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/it/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (26.07 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/lv/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (26.24 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/lt/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (26.24 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/hu/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (25.96 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/mt/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (24.44 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/nl/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (26.5 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/no/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_no.pdf)

polski (PL) (26.74 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/pl/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_pl.pdf)

português (PT) (25.66 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/pt/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_pt.pdf)

română (RO) (25.34 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/ro/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (26.25 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/sk/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.69 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/sl/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (26.23 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/fi/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (24.62 KB - PDF)

**First published:**

16/10/2012

**Last updated:**

21/07/2017

[View](/sv/documents/all-authorised-presentations/dacogen-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Dacogen Active substance decitabine International non-proprietary name (INN) or common name decitabine Therapeutic area (MeSH) Leukemia, Myeloid Anatomical therapeutic chemical (ATC) code L01BC08

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy.

## Authorisation details

EMA product number EMEA/H/C/002221 Marketing authorisation holder

Janssen-Cilag International N.V.

Turnhoutseweg 30 BE-2340 Beerse Belgium

Marketing authorisation issued 20/09/2012 Revision 18

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Dacogen : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (166.65 KB - PDF)

**First published:** 04/02/2013

**Last updated:** 02/10/2024

[View](/en/documents/procedural-steps-after/dacogen-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Dacogen : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/CHMP/3022/2020

English (EN) (86.94 KB - PDF)

**First published:** 30/04/2021

[View](/en/documents/pip-compliance/dacogen-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Dacogen-H-C-PSUSA-00009118-202005 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/230662/2021

English (EN) (125.68 KB - PDF)

**First published:** 30/04/2021

[View](/en/documents/scientific-conclusion/dacogen-h-c-psusa-00009118-202005-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Dacogen-H-C-PSUSA-00009118-201805 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/125694/2019

English (EN) (65.39 KB - PDF)

**First published:** 20/02/2019

[View](/en/documents/scientific-conclusion/dacogen-h-c-psusa-00009118-201805-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Dacogen-H-C-PSUSA-00009118-201605 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/51858/2017

English (EN) (68.7 KB - PDF)

**First published:** 01/03/2017

**Last updated:** 01/03/2017

[View](/en/documents/scientific-conclusion/dacogen-h-c-psusa-00009118-201605-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Dacogen-H-C-2221-P46-008: EPAR - Assessment Report

Adopted

Reference Number: EMA/291636/2016

English (EN) (1.07 MB - PDF)

**First published:** 07/06/2016

**Last updated:** 07/06/2016

[View](/en/documents/variation-report/dacogen-h-c-2221-p46-008-epar-assessment-report_en.pdf)

Dacogen-H-C-2221-PSUV-0011 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/393582/2014

English (EN) (60.4 KB - PDF)

**First published:** 29/07/2014

**Last updated:** 29/07/2014

[View](/en/documents/scientific-conclusion/dacogen-h-c-2221-psuv-0011-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Dacogen-H-C-2221-PSUV-0008 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/39712/2014

English (EN) (60.32 KB - PDF)

**First published:** 27/01/2014

**Last updated:** 27/01/2014

[View](/en/documents/scientific-conclusion/dacogen-h-c-2221-psuv-0008-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Dacogen : EPAR - Public assessment report

Adopted

Reference Number: EMA/620205/2012

English (EN) (820.18 KB - PDF)

**First published:** 16/10/2012

**Last updated:** 16/10/2012

[View](/en/documents/assessment-report/dacogen-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Dacogen

Adopted

Reference Number: EMA/461407/2012

English (EN) (62.19 KB - PDF)

**First published:** 20/07/2012

**Last updated:** 20/07/2012

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-dacogen_en.pdf)

#### Related content

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-370) on 8 June 2006. Dacogen was withdrawn from the Community register of orphan medicinal products in September 2024 at the end of the 12-year period of market exclusivity.

#### More information on Dacogen

- [EMEA-000555-PIP01-09-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000555-pip01-09-m06)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 09/12/2025

## Share this page

[Back to top](#main-content)